ClinicalTrials.gov
ClinicalTrials.gov Menu

Ultraviolet Light Therapy for Systemic Lupus Erythematosus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00004375
Recruitment Status : Unknown
Verified January 2004 by National Center for Research Resources (NCRR).
Recruitment status was:  Recruiting
First Posted : October 19, 1999
Last Update Posted : June 24, 2005
Sponsor:
Collaborator:
Louisiana State University Health Sciences Center in New Orleans
Information provided by:
National Center for Research Resources (NCRR)

Brief Summary:

OBJECTIVES:

I. Evaluate the mechanisms of ultraviolet A-1 light therapy in patients with systemic lupus erythematosus and normal controls.


Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus Procedure: ultraviolet A-1 light treatment Phase 2

Detailed Description:

PROTOCOL OUTLINE:

Treatment with ultraviolet A-1 light is administered 5 days a week for 6 weeks, at the lowest dose or frequency required to maintain a response. The dose and frequency are progressively decreased over the next 9 weeks.


Study Type : Interventional  (Clinical Trial)
Enrollment : 20 participants
Primary Purpose: Treatment
Study Start Date : September 1991

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Patients ages 15 to 70 with symptomatic systemic lupus erythematosus meeting American Rheumatism Association criteria and normal controls

--Prior/Concurrent Therapy--

No requirement for tetracycline or other photosensitizing drugs


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004375


Locations
United States, Louisiana
General Clinical Research Center and Charity Hospital (University of Louisiana) Recruiting
New Orleans, Louisiana, United States, 70112-2822
Contact: Hugh McGrath, Jr.    504-568-4630    hmcgra@lsuhsc.edu   
Alton Ochsner Medical Foundation Hospital Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Jawed Alam    504-842-3314      
Sponsors and Collaborators
National Center for Research Resources (NCRR)
Louisiana State University Health Sciences Center in New Orleans
Investigators
Study Chair: Hugh McGrath, Jr. Louisiana State University Health Sciences Center in New Orleans

Publications:
ClinicalTrials.gov Identifier: NCT00004375     History of Changes
Other Study ID Numbers: NCRR-M01RR05096-0002
LSUMC-1765
LSUMC-910067
First Posted: October 19, 1999    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: January 2004

Keywords provided by National Center for Research Resources (NCRR):
arthritis & connective tissue diseases
immunologic disorders and infectious disorders
rare disease
systemic lupus erythematosus

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases